After a tough year, shares of Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) have managed to rebound more than 29 percent in the last month, largely on the back of the announcement that the FDA had allowed it to pursue regulatory approval of its...
BRUSSELS (dpa-AFX) - Novo Nordisk announced the headline results from the
DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial
conducted to confirm the cardiovascular safety of Tresiba (insulin degludec)
compared to insulin...
Novo Nordisk said its new insulin Tresiba carries about the same risk of serious heart problems as Sanofi’s Lantus but offers significantly lower risk of dangerously low blood sugar in people with Type-2 diabetes.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Novo Nordisk A/S (NVO):